Vascular Endothelial Growth Factor Immunostaining Correlates with Postoperative Relapse and Survival in Non-Small Cell Lung Cancer

Yılmaz, Aydın; Ernam, Dilek; Ünsal, Ebru; Demırağ, Funda; Atikcan, Şükran; Taştepe, İrfan

doi:10.1016/j.arcmed.2007.04.005

Cited by 17 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VEGF is one of the most important angiogenic factors, and its expression is reported in approximately 40-90% of all NSCLC cases [15,16,21,33,34]. In our study, consistent with Yoo et al [35], VEGF staining was detected in more than 90% of all cases.…”

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

“…At every stage of angiogenesis, one of the most important and effective factors is Vascular Endothelial Growth Factor (VEGF) [15][16][17]. It has been shown that overexpression of VEGF in the NSCLC is associated with increased metastatic potential and adverse prognosis [15,17,18]. p53 tumor suppressor gene mutation is one of the most common genetic changes in many tumors including lung cancer, and a mutated p53 gene or overexpression of its protein have been demonstrated in these tumors [17][18][19][20][21].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Maspin, VEGF and p53 Expression in Small Biopsies of Primary Advanced Lung Cancer and Relationship with Clinicopathologic Parameters

Bircan

Kapucuoğlu

et al. 2010

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Maspin, one of the serine protease inhibitors, has been shown to inhibit tumor progression and metastasis. We aimed to investigate maspin, p53 and VEGF expression in patients with squamous cell carcinoma (SCC), adenocarcinoma (AC) and small cell lung carcinoma (SCLC). The study included 28 SCC, 18AC, 17 SCLC biopsy samples. We used the streptavidin biotin immunoperoxidase method to test for maspin, p53 and VEGF antibodies. Medical records of these patients were reviewed from archival files. Cytoplasmic maspin expression was detected in 89.3%, 77.8%, 52.9% of SCC, AC and SCLC, respectively. The rate was significantly higher in non-small cell lung cancer (NSCLC) and SCC than SCLC (p = 0.013, p = 0.021, respectively). The mean percentages of maspin expression were significantly higher in NSCLC, SCC and AC than in SCLC (p = 0.0001, p = 0.0001, p = 0.038, respectively). In ACs, maspin and p53 expressions were correlated, although this was not statistically significant (p = 0.053, r = 0.464), and maspin positive cases had a significantly higher T status compared to negative cases (p = 0.036). In SCC, the stage of disease was positively correlated with p53 (p = 0.007, r = 0.536) and negatively correlated with VEGF expression (p = 0.013, r = -0.498). Multivariate analysis demonstrated that stage of disease was a significant independent prognostic parameter in NSCLC (95% confidence interval: 1.067-3.969; p = 0.031). Although maspin expression is higher in SCC and AC, and is related with higher T status in AC, our data did not indicate its prognostic significance. Larger scale studies are needed to reveal the exact role of maspin in lung cancer pathogenesis.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Maspin, VEGF and p53 Expression in Small Biopsies of Primary Advanced Lung Cancer and Relationship with Clinicopathologic Parameters

Bircan

Kapucuoğlu

et al. 2010

Pathol. Oncol. Res.

View full text Add to dashboard Cite

show abstract

“…Vascular endothelial growth factor (VEGF) and angiopoietins are among the most important angiogenic factors [10]. VEGF is upregulated in various malignancies and has prognostic implications [11,12]. Angiopoietins, cooperating with VEGF, are also involved in tumor angiogenesis [13,14], although their precise roles and interplay in tumor development and progression have not been clearly defined [10].…”

Section: Introductionmentioning

confidence: 99%

Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer

et al. 2009

View full text Add to dashboard Cite

“…Allowing that VEGF introduces the sprouting of new blood vessels that supply the tumour with oxygen and nutrients, it is a novel strategy for treating esophageal carcinoma, and the results of the ongoing clinical trials in patients with esophageal carcinoma are eagerly awaited. Although encouraging data have emerged to support the use of antiangiogenic therapy in some cancers such as myeloma and glioma, poor tumor response has been reported in others [28][29][30][31] . One major problem confronting clinical trials of antiangiogenic therapy is the lack of an established surrogate marker to measure antiangiogenic activity in vivo in cancer patients.…”

mentioning

confidence: 99%

Expression of Livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma

Chen¹,

Ren²,

Li³

et al. 2008

WJG

View full text Add to dashboard Cite

Vascular Endothelial Growth Factor Immunostaining Correlates with Postoperative Relapse and Survival in Non-Small Cell Lung Cancer

Cited by 17 publications

References 20 publications

Maspin, VEGF and p53 Expression in Small Biopsies of Primary Advanced Lung Cancer and Relationship with Clinicopathologic Parameters

Maspin, VEGF and p53 Expression in Small Biopsies of Primary Advanced Lung Cancer and Relationship with Clinicopathologic Parameters

Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer

Expression of Livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma

Contact Info

Product

Resources

About